Alexion’s existing C5 complement inhibitor, targeted by biosimilar developers, is used to treat patients with paroxysmal nocturnal hemoglobinuria, but the biologic must be administered every 2 weeks versus ALXN1210’s proposed 8-week intravenous dosing schedule.
This week, Alexion Pharmaceuticals announced that the FDA has accepted for review a Biologics License Application for ALXN1210, a proposed long-acting C5 complement inhibitor, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Alexion says that it expects a regulatory decision on the product in February 2019.
PNH is an ultra-rare blood disorder that causes uncontrolled activation of the complement system and results in hemolysis—the destruction of red blood cells—which, in turn, can cause thrombosis, potentially leading to organ damage and early death.
Alexion’s existing C5 complement inhibitor, eculizumab (Soliris), is currently used to treat patients with PNH, but the biologic must be administered every 2 weeks (versus ALXN1210’s proposed 8-week intravenous dosing schedule, and a proposed once-weekly subcutaneous dosing option that will be the subject of an upcoming phase 3 study).
Click to read more about eculizumab.
Earlier this year, Alexion reported positive topline results from a phase 3 study that determined that patients receiving treatment with eculizumab can be safely and effectively switched to treatment with ALXN1210. In addition to demonstrating noninferiority to eculizumab in terms the primary endpoint—change in lactate dehydrogenase levels—the proposed drug was also noninferior to eculizumab in the proportion of patients with breakthrough hemolysis, change from baseline in quality of life as determined via the Functional Assessment of Chronic Illness Therapy Fatigue Scale, the proportion of patients avoiding transfusion, and the proportion of patients with stable hemoglobin levels.
Alexion’s executive vice president and head of research and development, John Orloff, MD, said in a statement that the company hopes to “establish ALXN1210 as the new standard of care for patients with PNH,” but it will remain to be seen whether payers will agree that a longer duration of action is worth a potentially higher cost; the brand-name Soliris already carries a list price of approximately $500,000 per patient per year, making the biologic one of the most expensive therapies in the world.
However, biosimilars for eculizumab may be on the horizon. The reference eculizumab, which is also approved to treat 2 other ultra-rare disorders, atypical hemolytic uremic syndrome and myasthenia gravis, is expected to lose patent protection in the United States and Europe within 3 years’ time.
The molecule is targeted by at least 1 biosimilar developer; Amgen is currently engaged in a phase 3 study in Spain that evaluates the efficacy and safety of its proposed biosimilar, ABP 959, versus the reference eculizumab in patients with PNH.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.